Navigation Links
Pharmaceutical Commercial Leaders Seek Global Benchmarks for More Informed Decision-Making
Date:5/21/2012

CHAPEL HILL, N.C., May 21, 2012 /PRNewswire/ -- Savvy vice presidents and directors across all pharmaceutical commercial functions are searching now for best-in-class organizational structures, critical activities, proven processes, and investment benchmarks that ensure sustained growth across global markets.

"In today's increasingly competitive health care environment, global leaders and managers need to have analysis from across the worldwide marketplace," says Best Practices CEO, Chris Bogan. "Information from one country or region is not enough."

To support pharmaceutical leaders tasked with global oversight of structuring, resourcing, and strategic planning, Best Practices, LLC launches Global Management Navigator within the Wizards & Analytics Search (http://www3.best-in-class.com/rw16.htm).

"The Global Management Navigator puts benchmarking research, insights and analysis from a worldwide perspective into leaders' hands and supports evidence-based and informed decision-making," Bogan explains. The new Wizard searches the Best Practice Database for global benchmarks in a specified function, group, process or role.

For example, one often-searched health care area is "medical science liaisons," a highly knowledgeable group who provide critical medical information to the practicing community on behalf of the companies that manufacture new medicines and/or devices. To demonstrate the power of the new search Wizards in the Best Practice Database Global Management Navigator using the popular search term "medical science liaisons," simply:

How to Use the Global Management Navigator:


SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
(Date:10/20/2014)... 20 de octubre de 2014  PneumRx, Inc. ... de la pulmonología intervencional, anunció hoy la conclusión ... 3 meses antes de lo programado. El Estudio Clínico ... dispositivo de investigación (IDE) aprobada por la FDA ... de espiral de reducción de volumen pulmonar PneumRx ...
(Date:10/20/2014)... , Oct. 20, 2014  ResMed (NYSE: ... the ResMed Data Exchange program, a comprehensive suite ... equipment (HME) and other health care providers. ... access to critical patient information. It integrates valuable ... and U-Sleep™ patient management platforms with customers, in-house ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3ResMed Launches ResMed Data Exchange 2
... YORK, Dec. 20, 2010 Health organizations will undergo ... new rules and payment models, continuing cost pressures and ... Industry Issues of 2011 , published today by PwC,s ... of 1,000 U.S. adults, PwC found that consumers don,t ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) today ... 8:30 a.m. Eastern Time on Monday, December 20, to discuss ... in central retinal vein occlusion (CRVO) and the week 52 ... patients with diabetic macular edema (DME).  A press release will ...
Cached Medicine Technology:Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 2Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 3Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 4Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 5Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 6Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 7Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011 8Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study in Diabetic Macular Edema (DME) 2
(Date:10/22/2014)... Brownsville, TX (PRWEB) October 22, 2014 On ... will present its fourth annual family health and fitness fair ... Hispanic family physical activity and good nutrition for better health ... This event, which is free and open to the public, ... Street, in Brownsville, from 9:00 am to 1:00 pm. ...
(Date:10/22/2014)... October 22, 2014 Isabel Healthcare ... Allied Health Professions (ASAHP) Conference on October 22-24 in ... will participate in a panel discussion on Technology in ... Isabel Healthcare provides a diagnostic decision support tool and ... diagnosis skills of students and clinical learners. The Isabel ...
(Date:10/22/2014)... The United States is now mandating that all ... Africa land at one of five airports equipped ... In a statement released Tuesday, Homeland Security ... air passengers from Guinea, Liberia and Sierra Leone ... -- New York City,s Kennedy International Airport, Washington ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Best Cheap Hosting USA is among the most distinguished ... announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ) is the best ... world. , “iPower is one of the most reliable ... kinds of useful products for new and old clients. ... service and a number of features which will appeal ...
Breaking Medicine News(10 mins):Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2
... May 15 /PRNewswire-FirstCall/ - CRH Medical Corporation,(CRM:TSX-V) announced today ... Bay Shore, Long Island. This Center is the Company,s ... new markets that CRH has targeted for,expansion. The opening ... 2008 bringing the Company,s total number of Centers to ...
... lead unhealthy lifestyles are more likely to suffer from ... population-based study of more than 5,000 men and women ... journal BJU International. Researchers hope the results will help ... can be managed more effectively. , According to ...
... Revenue Increased 70.9% to $9.2 Million, CHENGDU, ... (OTC Bulletin Board: TYNP), a manufacturer and,supplier of ... today announced fiscal results for its third quarter ... quarter of 2008 increased 70.9% to approximately,$9.2 million ...
... to be Webcast Live at 2:00 p.m. ET Thursday, ... Inc.,(Nasdaq: CYNO ), a leading developer and manufacturer ... announced that its senior,management will present at the 2008 ... the Hilton New York., Cynosure,s presentation will be ...
... MONTVALE, N.J., May 15 Pain is a ... are an important option,for these patients. Physicians must ... the best outcomes for their patients., To ... the proper,opioid analgesic, the dual journals Current Clinical ...
... mouse model hint of new treatment strategies for the disease ... fat, the kind often found in baked and fried goods, ... The finding by University of California, Los Angeles, scientists is ... mouse model that closely mimics human cancer. , The fat ...
Cached Medicine News:Health News:CRH Medical Corporation opens Center in New York 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 2Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 3Health News:Obesity and unhealthy lifestyles linked to more complex urinary problems 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 2Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 3Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 4Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 5Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 6Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 7Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 8Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 9Health News:Tianyin Pharmaceutical Co., Inc. Announces Third Quarter 2008 Financial Results 10Health News:Cynosure to Present at 2008 Citi Investment Research Global Health Care Conference 2Health News:Treat Your Patients' Pain Effectively 2Health News:Lowering Dietary Fat May Help Prevent Prostate Cancer 2
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
Medicine Products: